Top Story
Sanofi to donate 100M doses of new flu vaccine
Protein Sciences' gene-based approach to vaccine development has drawn considerable support from the federal government. The government issued a $35 million contract to the vaccine company to help advance an entirely new approach to vaccine development that holds the promise of being far faster than the R&D methods currently in use. And that will give the government, and the world, a better shot at a rapid-fire response to future pandemics. Report
Latest News
Regulators approve a new jab for dogs
The USDA has approved the first new vaccine to protect dogs from the H3N8 flu virus. The virus evidently first jumped from horses to dogs about five years ago and is particularly lethal for canines... Read more...
Epidemiologists puzzled by swine flu's impact
As a bevy of vaccine makers around the world rush into the clinic with new swine flu vaccines, epidemiologists are still puzzling out how the new flu works and why many young people without any... Read more...
Novartis delayed on Menveo app
The FDA has asked Novartis for more information on its meningitis vaccine Menveo, which is likely to push back any approval date to late this year or early in 2010. And the manufacturer was quick to... Read more...
Vical shares jump as it aces swine flu study
Shares of Vical got a boost on Tuesday after the developer said its swine flu jab sailed through an animal study with positive results. Its stock shot up 20 percent on the news that the vaccine is... Read more...
Novavax shares skyrocket on European vax pact
Shares of Rockville, MA-based Novavax shot up more than 80 percent on Tuesday afternoon after the developer announced a licensing deal covering its use of virus-like particles in new vaccines.... Read more...
Transplant drug offers surprising boost for vaccines
A drug used to block immune cells from attacking transplanted organs also triggers the increased production of memory T-cells, and that could play a surprising role in boosting the effectiveness of... Read more...
Merck KGaA to test Stimuvax in breast cancer trial
Germany's Merck KGaA has launched a late-stage trial of the therapeutic vaccine Stimuvax in patients with breast cancer. Already in a Phase III study for non-small cell lung cancer, Merck is out to... Read more...
Panel recommends Intercell's new Japanese encephalitis jab
Less than three months after winning FDA approval, a U.S. immunization panel has put the Japanese encephalitis vaccine Ixiaro on a list of jabs recommended for American travelers. The Advisory... Read more...
Latest Comments
News Timeline
Breaking swine flu news
Want more information on the ongoing swine flu outbreak? Get breaking news and more details here. TimelineFrom The Network
Also Noted
Swine Flu
Novartis has produced the first batch of H1N1 vaccine in Europe using cell culture production methods. But a mass stockpile won't be ready for another two months. Report
Inovio Biomedical has forged a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate the company's DNA vaccine candidates against swine influenza A virus. Release
Some U.S. experts say that unlike Canada, America could distribute an H1N1 vaccine without an adjuvant to boost its effectiveness. Story
Vaccine Research
Read more >>Press Releases
- GSK further extends its product portfolio in the Middle East and North Africa
- Symetis raises $21 million
- Symetis Raises $21 Million
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
- Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Invest
